Astria Therapeutics’ (ATXS) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Astria Therapeutics (NASDAQ:ATXS) in a research report report published on Thursday,Benzinga reports. They currently have a $16.00 price target on the biotechnology company’s stock.

Several other equities analysts also recently weighed in on ATXS. JMP Securities began coverage on Astria Therapeutics in a research report on Friday, January 31st. They issued an “outperform” rating and a $26.00 target price for the company. Citizens Jmp raised Astria Therapeutics to a “strong-buy” rating in a research report on Friday, January 31st. Finally, Oppenheimer boosted their price objective on Astria Therapeutics from $26.00 to $28.00 and gave the stock an “outperform” rating in a research report on Thursday, November 14th. Six equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $25.67.

Astria Therapeutics Price Performance

NASDAQ ATXS opened at $6.44 on Thursday. The company has a market cap of $363.43 million, a P/E ratio of -3.08 and a beta of 0.67. The stock has a 50-day moving average of $7.70 and a two-hundred day moving average of $9.88. Astria Therapeutics has a 1-year low of $6.20 and a 1-year high of $16.90.

Hedge Funds Weigh In On Astria Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in ATXS. KLP Kapitalforvaltning AS acquired a new position in Astria Therapeutics in the fourth quarter valued at approximately $41,000. Tower Research Capital LLC TRC boosted its holdings in Astria Therapeutics by 109.2% in the fourth quarter. Tower Research Capital LLC TRC now owns 5,299 shares of the biotechnology company’s stock valued at $47,000 after purchasing an additional 2,766 shares in the last quarter. BNP Paribas Financial Markets acquired a new position in Astria Therapeutics in the fourth quarter valued at approximately $50,000. Virtus ETF Advisers LLC acquired a new position in Astria Therapeutics in the fourth quarter valued at approximately $65,000. Finally, Quest Partners LLC boosted its holdings in Astria Therapeutics by 180.8% in the third quarter. Quest Partners LLC now owns 9,004 shares of the biotechnology company’s stock valued at $99,000 after purchasing an additional 5,798 shares in the last quarter. 98.98% of the stock is owned by institutional investors and hedge funds.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.